source
- Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitorEli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
- European regulators recommend Sanofi's MS drug tolebrutinib for approval after US rejectionEuropean Medicines Agency officials issued a positive recommendation for tolebrutinib, an experimental multiple sclerosis therapy from Sanofi, after the U.S. FDA rejected the drug earlier this year…